99 related articles for article (PubMed ID: 28178623)
1. T-cell leukemia/lymphoma-1A predicts the clinical outcome for patients with stage II/III colorectal cancer.
Li H; Yan X; Liu L; Huang L; Yin M; Pan C; Zhang P; Qin H
Biomed Pharmacother; 2017 Apr; 88():924-930. PubMed ID: 28178623
[TBL] [Abstract][Full Text] [Related]
2. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
3. MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer.
Matsuyama T; Ishikawa T; Mogushi K; Yoshida T; Iida S; Uetake H; Mizushima H; Tanaka H; Sugihara K
Int J Cancer; 2010 Nov; 127(10):2292-9. PubMed ID: 20162577
[TBL] [Abstract][Full Text] [Related]
4. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
[TBL] [Abstract][Full Text] [Related]
5. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer.
Gao J; Li N; Dong Y; Li S; Xu L; Li X; Li Y; Li Z; Ng SS; Sung JJ; Shen L; Yu J
Oncogene; 2015 Jul; 34(31):4142-52. PubMed ID: 25362853
[TBL] [Abstract][Full Text] [Related]
6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
7. Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer.
Liu L; Yang Y; Zhou X; Yan X; Wu Z
Biomed Pharmacother; 2018 Mar; 99():645-654. PubMed ID: 29653487
[TBL] [Abstract][Full Text] [Related]
8. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
10. Stromal Expression of Vimentin Predicts the Clinical Outcome of Stage II Colorectal Cancer for High-Risk Patients.
Liu LG; Yan XB; Xie RT; Jin ZM; Yang Y
Med Sci Monit; 2017 Jun; 23():2897-2905. PubMed ID: 28611349
[TBL] [Abstract][Full Text] [Related]
11. High expression of COUP-TF II cooperated with negative Smad4 expression predicts poor prognosis in patients with colorectal cancer.
Wang C; Zhou Y; Ruan R; Zheng M; Han W; Liao L
Int J Clin Exp Pathol; 2015; 8(6):7112-21. PubMed ID: 26261604
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of perineural invasion in stages II and III colorectal cancer.
Zhou Y; Wang H; Gong H; Cao M; Zhang G; Wang Y
Pathol Res Pract; 2015 Nov; 211(11):839-44. PubMed ID: 26429129
[TBL] [Abstract][Full Text] [Related]
13. Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer.
Nagayoshi K; Ueki T; Tashiro K; Mizuuchi Y; Manabe T; Araki H; Oda Y; Kuhara S; Tanaka M
Oncol Rep; 2015 Feb; 33(2):539-46. PubMed ID: 25504183
[TBL] [Abstract][Full Text] [Related]
14. Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer.
Jiang Z; Wang Z; Xu Y; Wang B; Huang W; Cai S
Biosci Rep; 2010 Dec; 30(6):383-90. PubMed ID: 20001967
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.
Masuda T; Ishikawa T; Mogushi K; Okazaki S; Ishiguro M; Iida S; Mizushima H; Tanaka H; Uetake H; Sugihara K
Int J Oncol; 2016 Mar; 48(3):975-82. PubMed ID: 26783118
[TBL] [Abstract][Full Text] [Related]
17. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis.
Agesen TH; Sveen A; Merok MA; Lind GE; Nesbakken A; Skotheim RI; Lothe RA
Gut; 2012 Nov; 61(11):1560-7. PubMed ID: 22213796
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
19. RacGAP1 expression, increasing tumor malignant potential, as a predictive biomarker for lymph node metastasis and poor prognosis in colorectal cancer.
Imaoka H; Toiyama Y; Saigusa S; Kawamura M; Kawamoto A; Okugawa Y; Hiro J; Tanaka K; Inoue Y; Mohri Y; Kusunoki M
Carcinogenesis; 2015 Mar; 36(3):346-54. PubMed ID: 25568185
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.
Fukushima Y; Iinuma H; Tsukamoto M; Matsuda K; Hashiguchi Y
Oncol Rep; 2015 Feb; 33(2):573-82. PubMed ID: 25421755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
